Lori Leslie, MD, Discusses CAR T-cell therapy and DLBCL

Video

Lori Leslie, MD, of the John Theurer Cancer Center, sat down to discuss the relationship between chimeric antigen receptor (CAR) T-cell therapy and diffuse large B cell lymphoma (DLBCL) at the 61st American Society of Hematology (ASH) Annual Meeting & Exposition, held December 7-10, in Orlando, Florida.

Transcription:

So, I think in DLBCL right now CAR T-cell (therapy) is very exciting (and) really has revolutionized how we treat patients with relapsed/refractory disease. There’s some very interesting CAR T information being presented at ASH. 

I’m interested in the mechanisms of resistance. So even though CAR T is an effective therapy, long-term remissions overall are about 40%. So is it the loss of CD19, different CD19 epitopes, that leads to (patients’) progressions or lack of responses (that) is really changing development of CAR T(-cell therapy). 

How do we combine therapies? How do we create different targets? Maybe dual specific targets for CAR T(-cell therapy) to help increase the overall efficacy of long-term (complete responses) and potentially cure patients.

Recent Videos
Experts at Yale Cancer Center highlight ongoing trials intended to improve outcomes across mantle cell lymphoma, T-cell lymphoma, and other populations.
Yale’s COPPER Center aims to address disparities and out-of-pocket costs for patients, thereby improving the delivery of complex cancer treatment.
Non-Hodgkin lymphoma and other indolent forms of disease may require sequencing new treatments for years or decades, said Scott Huntington, MD, MPH, MSc.
Fixed-duration therapy may be more suitable for younger patients, while continuous therapy may benefit those who are older with more comorbidities.
A new clinical trial aims to offer a novel allogenic CAR T-cell product for patients with lymphoma closer to home.
Determining the molecular characteristics of one’s disease may influence the therapy employed in the first line as well as subsequent settings.
Related Content